For use with E0828 A needle tip and E0828 B gouge tip. Round knurled with threaded ended for tips. Most popular size or model.
Threaded ends permit guarding the needle and gouge within the handle. Set consists of one each : E0828 A needle tip, E0828 B gauge tip and E0828 C handle. Most popular size or model.
Battery operated single speed motorized handpiece, tip cover, supplied with 0.5 mm tungsten burr (E0815 0.5) and one battery size "AA".
5.5 mm disk shape burr. Diamond coated tip. Use with E0824 B handle.
Medicine Products:(Date:5/16/2008)...inhua-PRNewswire-FirstCall/ -- BMP,Sunstone Corpor...eting and,distribution pharmaceutical companies, t...e following conferences:, (1) The Roth Annual C... David Gao, Chief Executive Officer of the Co...ay 19, 2008, at 4:40 pm local time at the Reg...
(Date:5/16/2008)...rs at The University of Texas M. D. Anderson Cance...ills leukemia cells by shutting down their energy ...clinical study, Lauren Akers, D.O., postdoctoral f... Anderson, found that combining a novel glycolysis..., induced more than 90 percent cell death in human...
(Date:5/16/2008)...ice Announcement Available, RADNOR, Pa., May 16 /...nal Mental Health Month and Older Pennsylvanians M...) will offer an important message to senior,citize...ic service,announcement developed by Feeling Blue ...ealth problem of depression and to offer hope to o...
(Date:5/16/2008)...ire/ -- Tao Formulations announces the,official la... the Internal,Medicine 2008 conference in Washingt...on of years of research to develop a safe, all-nat... relieving menopausal symptoms., Company founder ...cian,and gynecologist, founded Tao Formulations (...
Breaking Medicine News(10 mins):Health News:BMP Sunstone Announces Participation in May Investor Conferences 2Health News:New drug combination brings 1-2 punch against acute leukemia 2Health News:Suicide Prevention Group Delivers Much-Needed Message to Pennsylvania's Elderly 2Health News:Tao Formulations Announces the Official Launch of Tao Harmony - Menopause Relief Formula 2... that a new extended-release formulation of metfor... diabetes as opposed// to the traditional twice a ...new drug, which is marketed under the brand name G...'s tolerance for higher doses of the drug, accordi...
...ted that patients who are at a high risk for devel...g a combination of vitamins E and C// plus ibuprof...in people who have a mutated gene for apolipoprote...on predisposing them to Alzheimer's disease. Re...
...ani Ramadoss made a reassuring announcement that w...HIV//. With the help of 48 additional centers to b...et of providing free anti-AIDS drugs to one lakh p...e a renewed thrust to India’s efforts in combating...
...rch conducted by the scientists at the University ...present in the air may have an adverse// effect on...found in the pollution from traffic exhaust, house..., cosmetics and clothes. Nanoparticles are atoms ...
Other Medicine News:(Date:5/15/2008)... 15 /- Medivation, Inc.,(Na...going Phase 1-2 clinical,trial of its novel androg...,in an oral presentation at the 44th American Soci...Chicago., Session title: New Targeted Strategie...and time: Monday, June 2 at 11:30 a.m. Central Tim...
(Date:5/15/2008)...ia, May 15 /- Cytopia Limit...r its upcoming oral,presentation on CYT997 at the ...nical Oncology (ASCO) will be accessible to the pu...om 9pm on Thursday 15 May (US EDT)., The oral pre... a novel,cytotoxic and vascular disrupting agent, ...
(Date:5/15/2008)... May 15 /- Sanofi-aventis,(...findings from the,landmark ATHENA study showed Mul...treatment of patients with atrial fibrillation or ...ar hospitalizations or death from any,cause by a s...ng the study,primary endpoint. The ATHENA results ...
(Date:5/15/2008)...Newswire/ -- CenterWatch, a publishing and,informa...bout clinical,trials, finds that investigative sit...data capture) systems. More than 75% of respondent...ey had been trained on three or more,EDC systems. ...veness of,their EDC training had improved., State...
Breaking Medicine Technology:Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 2Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 2Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 4Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 5Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 6Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 7CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence 2Robbins 26 Myers to Present at Merrill Lynch Growth Industrials Conference December 13 2007 7805 1FDA Advisory Committee Votes Unanimously to Recommend Approval of Tetrabenazine for Chorea Associated With Huntington Disease 7800 1FDA Advisory Committee Votes Unanimously to Recommend Approval of Tetrabenazine for Chorea Associated With Huntington Disease 7800 2Longs Drugs Plans to Become the First Retailer in Hawaii With Walk in Medical Clinics 7795 1Longs Drugs Plans to Become the First Retailer in Hawaii With Walk in Medical Clinics 7795 2Longs Drugs Plans to Become the First Retailer in Hawaii With Walk in Medical Clinics 7795 3Insmed Appoints Dennis M Lanfear to Board Of Directors 2096 1Insmed Appoints Dennis M Lanfear to Board Of Directors 2096 2Insmed Appoints Dennis M Lanfear to Board Of Directors 2096 3...resented at Federation of,Clinical Immunology Soci...June 11, 2007 /PRNewswire-FirstCall/ --,Orchestra ...d today,positive new data from its completed Phase...tional T Cell Receptor (TCR) peptide,vaccine for t...osis,(MS). The new data, presented last week at th...
...ngress of European Hematology,Association (EHA) -,...all/ --,Immunomedics, Inc. , a biopharmaceutical c... to treat cancer and other serious,diseases, today...s,of EHA in Vienna, Austria, showed positive respo... treated with a new,radioimmunotherapy (RAIT) usin...
Other Medicine Technology:Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 2Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 3Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 4Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 5Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 2Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 3Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 4Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 5